http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1880220-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a490020fd2580d5f04cbe4ea55b65c3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7de02e4b28736bfb52de8bb358be203e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96436 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
| filingDate | 2006-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5ce0c4f070e16380437d7811050ca54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc525bd9d963ad8df184d84ad341b516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_247f160e37c973d39455e3df30f79954 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e996306d0e1312de6d321414e3c84b4 |
| publicationDate | 2008-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1880220-A2 |
| titleOfInvention | Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease |
| abstract | An antigen-specific T-ceII response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor for development of deleterious immune responses, which may be confirmed by functional assays. For example, the distinction between production of regulatory or inflammatory cytokines by T cells may dissect the type of immune response which is being induced: the survival of transplanted islet cells used to treat type 1 diabetes may be monitored, loss of the transplant by graft rejection (i.e., an alloantigen target) may be distinguished from autoimmune disease (i.e., a self or host antigen target). |
| priorityDate | 2005-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.